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Background: Nintedanib is a clinically approved multikinase receptor inhibitor to treat non-small cell lung cancer with
adenocarcinoma (ADC) histology in combination with docetaxel, based on the clinical benefits reported on ADC but not on
squamous cell carcinoma (SCC), which are the two most common histologic lung cancer subtypes.
Methods: We examined the potential role of tumour-associated fibroblasts (TAFs) in the differential effects of nintedanib in ADC
and SCC. Because TAFs are largely quiescent and activated in histologic sections, we focused on the antifibrotic effects of
nintedanib on TAFs stimulated with the potent fibroblast activator TGF-b1, which is upregulated in lung cancer.
Results: Nintedanib dose-dependently inhibited the TGF-b1-induced expression of a panel of pro-fibrotic activation markers in
both ADC-TAFs and control fibroblasts derived from uninvolved lung parenchyma, whereas such inhibition was very modest in
SCC-TAFs. Remarkably, nintedanib abrogated the stimulation of growth and invasion in a panel of carcinoma cell lines induced by
secreted factors from activated TAFs in ADC but not SCC, thereby supporting that TGF-b signalling and aberrant TAF–carcinoma
cross-talk is regulated by different mechanisms in ADC and SCC.
Conclusions: These results reveal that nintedanib is an effective inhibitor of fibrosis and its associated tumour-promoting effects in
ADC, and that the poor antifibrotic response of SCC-TAFs to nintedanib may contribute to the differential clinical benefit
observed in both subtypes. Our findings also support that preclinical models based on carcinoma–TAF interactions may help
defining the mechanisms of the poor antifibrotic response of SCC-TAFs to nintedanib and testing new combined therapies to
further expand the therapeutic effects of this drug in solid tumours.
Lung cancer is the leading cause of cancer-related deaths in both
men and women in industrialised countries, with a 5-year survival
rate of only B15%. Histologically, B85% of lung cancer patients
are classified as non-small cell lung cancer (NSCLC), which are
further subdivided into adenocarcinoma (ADC; B50%), squamous
cell carcinoma (SCC; B40%) and other less frequent subtypes
(Ferlay et al, 2013; Chen et al, 2014). Even though both ADC and
SCC are epithelial in origin, it is increasingly acknowledged that
carcinoma cells need to surround themselves by an aberrant stiff
desmoplastic stroma to develop a tumour (Hanahan and
Weinberg, 2011; Bissell and Hines, 2012). Likewise, a large body
of work indicates that tumour-associated fibroblasts (TAFs), which
are the most abundant stromal cell type, are implicated in many
critical steps of cancer progression including initiation, growth,
invasion, metastasis, stemness, immunosuppression and even
resistance to therapies (Kalluri and Zeisberg, 2006; Ohlund et al,
2014; Lugo et al, 2016; Labernadie et al, 2017). Accordingly,
targeting the aberrant carcinoma–TAF interactions is emerging as
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a promising therapeutic strategy in NSCLC and other solid
tumours (Ohlund et al, 2014; Lugo et al, 2016).
Nintedanib is a small molecule inhibitor of multiple tyrosine
kinases that has been recently approved for second-line treatment
after chemotherapy failure combined with the cytotoxic docetaxel
in patients with advanced lung ADC, owing to the selective positive
therapeutic results reported in ADC (but not in SCC) patients in a
phase III clinical trial (LUME-Lung 1) (Reck et al, 2014).
Nintedanib (also known as BIBF 1120) competitively binds to
the ATP-binding sites within the kinase domains of VEGFR
receptors (VEGFR) 1–3, PDGFR a/b, and FGFR 1–4. In addition,
nintedanib inhibits Src family tyrosine kinases (Src, Lck, Lyn), Flt-3
and RET (Hilberg et al, 2008; Wollin et al, 2014; Awasthi and
Schwarz, 2015). In agreement with its initial design as a next
generation antiangiogenic drug, previous studies with lung cancer
xenografts reported that nintedanib exhibits strong antiangiogenic
functions through a direct effect on cell types involved in
angiogenesis, including endothelial cells, pericytes and smooth
muscle cells (Hilberg et al, 2008). In addition, it was reported that
nintedanib exhibits further anticancer effects by reducing tumour
growth and metastasis (Hilberg et al, 2008; Cenik et al, 2013).
These previous observations highlight the ability of nintedanib to
target multiple cell types within the tumour microenvironment,
which has been associated with the simultaneous inhibitory effects
of this drug on several signalling pathways (Wollin et al, 2014;
Huang et al, 2016). However, the biological processes underlying
both the positive therapeutic effects of nintedanib in ADC and the
lack of such effects in SCC remain unknown.
In addition to lung ADC, nintedanib has been recently approved
to treat patients with idiopathic pulmonary fibrosis (IPF), based on
its ability to slow the progression of this rare disease in clinical
trials (Richeldi et al, 2014; Wollin et al, 2015). Although lung ADC
and IPF are markedly distinct both clinically and biologically,
pulmonary tissues in both diseases have in common an abundant
stiff desmoplastic stroma rich in collagen and activated fibroblasts/
myofibroblasts (King et al, 2011). Because IPF-progression has
been strongly associated with the persistent proliferation and
pathologic activation of lung fibroblasts (King et al, 2011; Wollin
et al, 2015), analysing the effects of nintedanib on this cell type has
been the subject of increasing preclinical research. In vitro studies
have shown that nintedanib interferes with important fibroblast-
dependent hallmarks of lung fibrosis including fibroblast pro-
liferation, activation and deposition of extracellular matrix
components in response to pro-fibrotic cytokines like PDGF or
TGF-b (Wollin et al, 2015). These studies clearly indicate that
nintedanib has a direct impact on fibroblast functions, thereby
suggesting that this drug may also have direct inhibitory effects on
TAFs. However, to our knowledge, no studies have been under-
taken to examine the impact of nintedanib on activated TAFs.
We have recently shown that ADC-TAFs and SCC-TAFs are
activated in vivo and overexpress activation markers compared to
paired control fibroblasts in vitro. Yet ADC-TAFs and SCC-TAFs
exhibited also distinct phenotypic alterations in terms of growth
regulation and integrin signalling (Puig et al, 2015; Lugo et al,
2016). Therefore, given the known direct effects of nintedanib on
lung fibroblasts and the distinct aberrant phenotypes of ADC-
TAFs and SCC-TAFs, we hypothesised that the selective
therapeutic effects of nintedanib on ADC may be due, at least in
part, to a larger impact of this drug on ADC-TAFs compared to
SCC-TAFs. To test this hypothesis, we examined the inhibitory
effects of nintedanib in lung TAFs from ADC and SCC patients as
well as lung fibroblast from non-malignant tissue upon stimulation
with either growth factors or TGF-b1 in terms of growth and
activation, respectively. Moreover we examined the potential
inhibitory role of nintedanib on the tumour-promoting effects of
activated TAFs in terms of growth and invasion in a panel of ADC
and SCC cell lines.
MATERIALS AND METHODS
Tissue samples and primary human lung TAFs. Lung tissue
samples were obtained from a cohort of 20 early stage NSCLC
surgical patients (10 ADC, 10 SCC) prior to 2013 at the Hospital
Clinic de Barcelona (HCB, Spain) with the approval of the Ethics
Committees of the HCB and the Universitat de Barcelona. All
patients gave their informed consent. Selected patients were male,
chemo-naı̈ve, Caucasian, X55 years old, and current smokers with
confirmed ADC or SCC diagnosis (additional clinical character-
istics of patients are available elsewhere (Vizoso et al, 2015)).
Tumour samples were collected and divided into two parts. One
part was paraffin-embedded for histologic analysis and the
remaining was used to isolate TAFs by outgrowth of tissue
explants (Puig et al, 2015). The mesenchymal origin of the primary
fibroblasts was confirmed by their positive and negative immuno-
fluorescence staining with vimentin and pan-cytokeratin anti-
bodies, respectively (Vizoso et al, 2015).
Histology. Immunohistochemical analyses of Ki-67 and a-SMA
were performed on tissue sections from our cohort using the Bond
automated immunohistochemistry system (Leica Microsystems,
Wetzlar, Germany) as previously described (Puig et al, 2015;
Vizoso et al, 2015; Lugo et al, 2016). Primary antibodies included
anti-a-SMA (1A4) and anti-Ki-67 (MIB-1, Dako, Cambridge, UK).
Nuclei were counterstained with haematoxylin. Histological
stainings were imaged with a bright-field microscope (BX43)
coupled to a digital camera (DP72) using a  40 objective
(Olympus, Japan). All image processing was carried out with
ImageJ (Abramoff et al, 2004).
Cell culture. The human fibroblast cell line CCD-19Lu obtained
from normal pulmonary tissue (ATCC, USA), patient-derived
primary lung TAFs and paired fibroblasts from uninvolved
pulmonary tissue were maintained in DMEM-based fibroblast
culture medium as described elsewhere (Bertolini et al, 2015; Puig
et al, 2015). Data from paired fibroblasts and CCD-19Lu were
pooled and used as control fibroblasts based on previous results
from our group (Puig et al, 2015). Fibroblasts were used up to
passage 10 (CCD-19Lu) or 6 (primary fibroblasts) to avoid
replicative senescence (Navab et al, 2011). All experiments with
fibroblasts were carried out on tissue culture plastic substrata
coated with 0.1 mg ml 1 collagen-I solution (Millipore, Billerica,
MA, USA) overnight at 4 1C. Unless otherwise indicated,
fibroblasts were seeded at 8 103 cells cm 2. To induce either
proliferation or activation, fibroblasts were stimulated with 10%
FBS (Gibco, Waltham, MA, USA) or 2.5 ng ml 1 human
recombinant human TGF-b1 (R&D Systems, Minneapolis, MN,
USA), respectively, concomitantly with increasing doses of
nintedanib. Nintedanib (BIBF 1120) was provided by Boehringer
Ingelheim Pharma GmbH & Co (Vienna, Austria), was diluted in
DMSO and used at concentrations 0.5–5 mM based on previous
studies (Hilberg et al, 2008; Wollin et al, 2014; Rangarajan et al,
2016; Shochet et al, 2016). For flow cytometry experiments,
fibroblasts were seeded in fibroblast culture medium for 24 h and
maintained in either 0% FBS (serum-free) or 10% FBS medium in
the presence of increasing nintedanib doses for 5 days with a media
change at day 3.
A panel of lung carcinoma cell lines derived from either ADC
(H1437, H522) or SCC (SK-MES-1, H520) (ATCC) patients were
used to examine the tumour-promoting effects of TAFs treated with
nintedanib. All carcinoma cell lines were wild-type EGFR and KRAS
(Blanco et al, 2009) to mimic critical genetic aspects of lung ADC
patients that may be treated with nintedanib in the clinic (Bronte
et al, 2016). Cancer cells were maintained in RPMI-1640-based
medium supplemented with 10% of FBS as reported elsewhere
(referred to as epithelial culture medium) (Lugo et al, 2016).
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Conditioned medium. Fibroblasts were seeded as 8 103
cells cm 2 in 60 cm2 Petri dishes in serum-free fibroblast medium
supplemented with 2.5 ng ml 1 TGF-b1 with our without 2 mM
nintedanib for 3 days. Next, culture medium was washed and
replaced with nintedanib-free and serum-free fibroblast culture
medium for 48 h. Afterwards, the conditioned medium (CM) was
collected, centrifuged to remove suspended cells and stored at
 20 1C until use.
Fibroblast cell number density and viability. The number
density of viable fibroblasts was assessed with the trypan blue
exclusion assay using a hemocytometer (Mesner et al, 1992). The
percentage of viable fibroblasts was assessed as the ratio of viable
cell number density with respect to total cell number density.
Cell cycle analysis. DNA histograms of single fibroblasts were
obtained by flow cytometry (LSRFortessa, BD Biosciences, San Jose,
CA, USA), and the percentages of cycling fibroblasts (i.e., cells in S or
G2/M phases) were assessed with FACSDiva Software v6.1.3 (BD
Biosciences) as described elsewhere (Puig et al, 2015; Lugo et al, 2016).
Quantitative PCR with reverse transcription. RNA extraction
and reverse transcription was conducted as previously reported by
our group (Vizoso et al, 2015). Real-time PCR reactions were
performed on 20 ng of each cDNA sample using TaqMan Gene
Expression Master Mix and TaqMan gene-specific primer pairs
and probes (Applied Biosystems, USA) for COL1A1, COL3A1 and
POLR2A (used as a housekeeping gene). Relative gene expression
with respect to the housekeeping gene was assessed as 2DCt
(Livak and Schmittgen, 2001).
Western blotting. Fibroblasts were lysed in extraction buffer
supplemented with phosphatase and protease inhibitors as
described before (Puig et al, 2015). Equal protein amounts were
separated on a 10% Mini-PROTEAN TGX precast gels (Bio-Rad,
Hercules, CA, USA), transferred to a PVDF membrane (GE
Healthcare, Little Chalfont, UK), blocked and incubated overnight
with suitable primary antibodies including anti-a-SMA (Sigma, St
Louis, MO, USA), P4HA2 (Proteintech Europe, Manchester, UK)
or b-actin (Sigma, used as loading control). Protein bands were
labelled and visualised by chemiluminescence in a digital imaging
system (ImageQuant LAS 4000, GE Healthcare). Protein band
intensities were quantified with ImageJ and normalised to the
corresponding loading control.
Assessment of IC50 values describing the antiproliferative and
antifibrotic effects of nintedanib in lung fibroblasts. Selected
quantitative assays (fold cell number, COL1A1 and COL3A1
expression) were used to compute IC50 values indicative of the
antiproliferative and antifibrotic effects of nintedanib, respectively.
For this purpose, the data corresponding to the measurements
from each assay (y) at different nintedanib concentrations (x) were
fitted to an exponential decay function (y¼ yoþ ae b  x, where yo,
a and b were the fitting parameters) with SigmaPlot (Systat
Software, USA), and used to assess IC50¼  ln0.5/b. The error
sIC50 associated with the calculation of IC50 was assessed using
error propagation (Taylor, 1997) as the absolute value of sIC50¼
sb  ln0.5/b2, where sb is the uncertainty of the b fitting.
Carcinoma cell growth stimulated by CM from TAFs. Carci-
noma cell growth stimulated by CM from activated TAFs was
assessed using protocols previously described by our group (Lugo
et al, 2016). Briefly, for each cancer cell line, cancer cells were
plated at 1.1 104 cells cm 2 in six-well plates and grown in 2 ml
of a 1 : 1 mixture of CM and serum-free epithelial culture medium
for 3 days. A 1 : 1 mixture of serum-free fibroblast/epithelial culture
medium was used as (basal) control medium. Afterwards, cells
were fixed with 4% PFA and their nuclei counterstained with
Hoechst 33342 (Molecular Probes, Eugene, OR, USA). Fluorescent
nuclei were imaged and counted with ImageJ. Cell number density
was assessed as the average nuclear density/image.
Carcinoma cell invasion stimulated by CM from TAFs. Cancer
cells were seeded on Matrigel-coated filter-inserts as 15 104
cells cm 2 in serum-free epithelial culture medium as described
(Lugo et al, 2016). CM or control medium was added to the lower
Transwell compartment. After 48 h, cells were fixed with 100%
methanol and incubated with 0.5% crystal violet (Sigma). Cells that
had invaded into the lower side of the filter were imaged by a
phase-contrast microscope provided with a colour camera.
Invasion was computed as the average crystal violet positive
area/image. All image processing was conducted with ImageJ.
Statistical analysis. Two group comparisons were performed with
Student’s t-test (SigmaPlot). Statistical significance was assumed at
Po0.05. All experiments were conducted as triplicates. All data
shown are mean±s.e.
RESULTS
Nintedanib inhibits both growth and activation of control lung
fibroblasts. To mimic either a pro-growth or a pro-fibrotic stiff
microenvironment in vitro, we stimulated fibroblasts cultured on
collagen-coated tissue culture plastic with either 10% FBS (which is
rich in the fibroblast mitogen PDGF (Freshney, 1994)) or
2.5 ng ml 1 of the potent fibroblast activator TGF-b1 (Hinz
et al, 2012), respectively. As expected, such stimulations induced a
robust increase in either fibroblast proliferation (10% FBS) or
activation (TGF-b1) (Supplementary Figure S1). To identify a
suitable dose range of nintedanib, we first examined the impact of
this drug on the viability and growth of control fibroblasts
(Figure 1). Nintedanib did not compromise the viability of
fibroblasts cultured in 10% FBS for 5 days up to 5mM
(Figure 1A). In contrast, nintedanib prevented the increase in
fibroblast population upon mitogenic stimulation with 10% FBS in
a dose-dependent manner (Figure 1B), whereas DMSO vehicle did
not (Supplementary Figure S1). To confirm the antiproliferative
effects of nintedanib, we analysed the percentage of cycling
fibroblasts by flow cytometry. In qualitative agreement with our
fibroblast number density data, nintedanib downregulated the rise
in cycling fibroblasts upon stimulation with 10% FBS for 5 days
(Figure 1C). A marked drop in cycling fibroblasts was also
observed after only 12 h upon 2mM nintedanib treatment,
indicating that this drug induces an early growth arrest in
fibroblasts (Figure 1D).
We next examined the antifibrotic effects of nintedanib by
assessing the expression of a panel of pro-fibrotic markers
including alpha-smooth muscle actin (a-SMA), fibrillar collagens
(COL1A1 and COL3A1) and prolyl-4-hydroxylase a subunit 2
(P4HA2) – an essential enzyme for collagen biosynthesis that is
upregulated by TGF-b (Koslowski et al, 2003; Kalluri and Zeisberg,
2006) – by either western blotting or qRT–PCR (Kalluri and
Zeisberg, 2006; Hinz et al, 2012; Ohlund et al, 2014) in control
fibroblasts stimulated with TGF-b1 or DMSO vehicle for 3 days.
Nintedanib downregulated the marked induction of both COL1A1
and a-SMA upon concomitant stimulation with TGF-b1 in a dose-
dependent fashion (Figure 1E and F), whereas DMSO vehicle did
not (Supplementary Figure S1). Likewise nintedanib dose-depen-
dently reduced both COL3A1 and P4HA2 expression in control
fibroblasts (Figure 1G and H). Remarkably nintedanib even
reduced COL1A1 and a-SMA in control fibroblasts pre-activated
with TGF-b1 for 3 days (Figure 1I and J). These results underscore
the robust inhibitory effects of this drug on the expression of both
fibrillar collagens and collagen-related genes. Altogether our results
expand previous observations of the antiproliferative and anti-
fibrotic effects of nintedanib in normal and IPF-derived lung
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Figure 1. Antiproliferative and antifibrotic effects of nintedanib in control lung fibroblasts. (A) Percentage of viable fibroblasts cultured with 10%
FBS for 5 days with increasing concentrations of nintedanib (n¼ 3). (B and C) Fold cell number (B, n¼ 5) and percentage of cycling cells (i.e., cells in
S or G2/M) (C, n¼ 4) of fibroblasts cultured as in A. Continuous line in B corresponds to the fitting of an exponential decay function that was used
to assess IC50 shown in Table 1. (D) Percentage of cycling fibroblasts cultured for 12 h with 10% FBS in the absence or presence of 2 mM nintedanib
(n¼3). (E) Fold mRNA expression of COL1A1 in fibroblasts stimulated with 2.5 ng ml 1 TGF-b1 for 3 days with increasing concentrations of
nintedanib (n¼ 5). (F) Left, representative western blot analysis of a-SMA and b-actin (loading control) of fibroblasts cultured as in E. Right,
densitometry analysis of a-SMA expression normalised to b-actin (n¼ 5). (G and H) Fold mRNA expression of COL3A1 (G) and western blot analysis
of P4HA2 (H) in fibroblasts cultured as in (E) (n¼4). (I and J) Expression of COL1A1 and a-SMA in fibroblasts pre-activated with 2.5 ng ml-1 TGF-b1
for 3 days and subsequently treated with 2.5 ng ml 1 TGF-b1 in the absence or presence of 2 mM nintedanib (n¼3). Continuous lines in (E, G and I)
correspond to fittings of an exponential decay function, which elicited IC50 values shown in Table 1 (for E and G) and 0.74mM for I. *Pp0.05,
**Pp0.01 and ***Pp0.005 with respect to 0mM nintedanib were determined by Student’s t-test.
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fibroblasts (Hostettler et al, 2014; Wollin et al, 2014; Huang et al,
2016; Rangarajan et al, 2016), and reveal that such inhibitory
functions are characterised by IC50 B0.8–1 mM (Table 1), which is
comparable to the maximum nintedanib concentration reported in
in vivo studies with this drug (Hilberg et al, 2008).
SCC-TAFs exhibit lower antifibrotic responses to nintedanib
than ADC-TAFs, but similar antiproliferative effects. Patient-
derived lung TAFs overexpress activation markers compared to
paired control fibroblasts in both ADC and SCC (Navab et al,
2011; Vizoso et al, 2015; Lugo et al, 2016). Yet we recently reported
distinct phenotypic alterations in TAFs from both subtypes,
suggesting that they could exhibit subtype-specific responses to
nintedanib. To examine this possibility, we first stimulated ADC-
TAFs and SCC-TAFs with 10% FBS in the presence of increasing
doses of nintedanib or DMSO vehicle. As in control fibroblasts,
nintedanib did not compromise the viability of TAFs up to 5 mM
(Figure 2A). In further agreement with control fibroblasts,
nintedanib dose-dependently prevented the increase in both
fibroblast number (Figure 2B) and percentage of cycling fibroblasts
(Figure 2C) upon 10% FBS stimulation, whereas DMSO vehicle did
not (Supplementary Figure S2). Such marked impact in the cell
cycle could be observed at 12 h upon treatment (Figure 2D),
revealing that nintedanib elicits an early growth arrest also in
TAFs. These experiments showed that the antiproliferative effects
of nintedanib in TAFs were quantitatively similar in both ADC and
SCC, eliciting comparable IC50 values to each other that were also
close to that found in control fibroblasts (Table 1).
Unlike growth inhibition, even though both ADC-TAFs and
SCC-TAFs became activated upon TGF-b1 stimulation
(Supplementary Figure S3), nintedanib inhibition of TAF activa-
tion in response to TGF-b1 was consistently larger in ADC-TAFs
than SCC-TAFs in all the pro-fibrotic markers examined (i.e.,
fibrillar collagens (Figure 3A and B), a-SMA (Figure 3C) and
P4HA2 (Figure 3D)) with statistical significance at different
nintedanib concentrations, whereas no expression changes were
reported upon treatment with DMSO vehicle (Supplementary
Figure S2). Such differential antifibrotic responses in TAFs elicited
IC50 values for COL1A1 and COL3A1 that were 2.2- and 1.4-fold
higher in SCC-TAFs than ADC-TAFs, respectively (Table 1). Since
IC50 values for both fibrillar collagens were very similar in ADC-
TAFs and control fibroblasts (Table 1), our data reveal for the first
time that SCC-TAFs exhibit a poor antifibrotic response to
nintedanib, whereas ADC-TAFs exhibit a normal antifibrotic
response to this drug.
Lung TAFs are quiescent and activated in vivo, supporting that
the subtype-specific antifibrotic function of nintedanib in TAFs
may be pathologically relevant. The marked antiproliferative and
antifibrotic responses to nintedanib observed in SCC-TAFs and
ADC-TAFs in vitro raised the question of what of these effects
might be more relevant in vivo. To shed light on this issue, we
analysed the proliferative and activation status of TAFs in
histologic sections from the same patient cohort used to obtain
primary TAFs. Our histologic analysis revealed that TAFs are
largely negative for the proliferation marker Ki-67 in both ADC
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Figure 2. Antiproliferative effects of nintedanib in ADC-TAFs and SCC-TAFs. (A) Viability of TAFs cultured with 10% FBS for 5 days in the
presence of increasing nintedanib concentrations (n¼ 3 ADC, 3 SCC). (B–D) Antiproliferative effects of nintedanib were assessed in terms of fold
TAF number (B; n¼3 ADC, 3 SCC) and percentage of cycling TAFs (C; n¼ 5 ADC, 4 SCC) as in Figure 1. (D) Percentage of cycling TAFs (n¼ 2
ADC, 2 SCC; pooled) after 12 h in the presence or absence of 2 mM nintedanib. Continuous lines in B and C correspond to fittings to an exponential
decay function, which were used to assess IC50 values shown in Table 1. *Pp0.05, **Pp0.01 and ***Pp0.005 with respect to 0 mM nintedanib were
determined by Student’s t-test.
Table 1. Nintedanib IC50 (mM) values characterising the
antiproliferative and antifibrotic effects on control fibroblasts
and TAFs (mean±s.e.)
Assay Control fibroblasts ADC-TAFs SCC-TAFs
Proliferation 0.93±0.09 0.96±0.09 1.09±0.05
COL1A1 1.1±0.3 1.05±0.07 2.3±0.6
COL3A1 0.80±0.03 0.74±0.15 1.0±0.1
Abbreviations: ADC¼ adenocarcinoma; SCC¼ squamous cell carcinoma; TAF¼ tumour-
associated fibroblasts. IC50 (mM) values were computed from Figure 1B, E and G (control
fibroblasts) and Figures 2B and 3A and B (TAFs).
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Ki-67 positive (Figure 4 and Supplementary Figure S4). In contrast,
virtually all TAFs were positive for the activation marker a-SMA in
both ADC and SCC (Figure 4), in agreement with previous
observations from our group (Puig et al, 2015). Because TAFs are
largely quiescent and activated in histologic sections, it is
conceivable that the differential antifibrotic effects of nintedanib
on ADC-TAFs and SCC-TAFs may be more therapeutically
relevant than its antiproliferative function.
Nintedanib abrogates the increase in cancer cell growth and
invasion elicited by conditioned medium from activated TAFs
in ADC but not SCC. To test the latter interpretation, we assessed
the inhibitory impact of nintedanib in two critical pro-tumouri-
genic effects of activated TAFs: stimulation of growth and invasion
of carcinoma cells. For this purpose, we stimulated either ADC-
TAFs or SCC-TAFs for 3 days with TGF-b1 in the presence or

















































































































































Figure 3. Antifibrotic effects of nintedanib in ADC-TAFs and SCC-TAFs. Antifibrotic effects were assessed in terms of expression of a panel of
activation markers including fibrillar collagens COL1A1 (A; n¼ 6 ADC, 8 SCC) and COL3A1 (B; n¼6 ADC, 7 SCC), a-SMA (C; n¼6 ADC, 6 SCC)
and P4HA2 (D; n¼5 ADC, 5 SCC) upon stimulation with 2.5 ng ml 1 TGF-b1 for 3 days in the presence of increasing nintedanib concentrations as
in Figure 2. Continuous lines in (A and B) correspond to fittings to an exponential decay function, which were used to assess IC50 values shown in
Table 1. #Pp0.05 and ###Pp0.005 in ADC-TAFs compared to SCC-TAFs, as determined by Student’s t-test. *Pp0.05 and ***Pp0.005 with












Figure 4. Proliferative and activation status of TAFs in vivo. Illustrative images of Ki-67 and a-SMA stromal stainings in histologic sections from
ADC and SCC patients obtained with a  40 objective. Arrowheads point to spindle-shaped nuclei characteristic of fibroblasts. Additional images
from other patients are shown in Supplementary Figure S4.
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SCC-TAFs (Table 1), washed the medium, replaced it with
nintedanib-free and serum-free fibroblast medium, and collected
the corresponding CM as outlined in Figure 5A. In these
conditions, no significant changes in fibroblast number were
detected regardless of the presence or absence of nintedanib
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Figure 5. Nintedanib modulation of the tumour-promoting effects of activated TAFs. (A) Outline of the experimental design used to assess the
growth (top right) and invasion (bottom right) of carcinoma cell lines stimulated with conditioned medium (CM) from TAFs activated with
2.5 ng ml 1 TGF-b1 for 3 days in the presence or absence of 2 mM nintedanib and subsequently maintained in serum-free and nintedanib-free
medium for 2 days. (B and C) Average fold cell number per field of a panel of wild-type (wt) EGFR and KRAS carcinoma cell lines derived from ADC
(H1437, H522) (B) or SCC (SK-MES-1, H520) (C) patients upon stimulation with CM from ADC-TAFs (nX4) or SCC-TAFs (nX4), respectively,
obtained as described in A. (D and E) Average fold invasion of the same panel of ADC (D) or SCC (E) carcinoma cell lines induced by different
types of CM (nX4 for ADC-TAFs and SCC-TAFs) as in (B and C). (F) Growth and invasion of SCC cells (H520) induced by the CM of ADC-TAFs
(n¼3). (G) Growth and invasion of ADC cells (H1437) induced by the CM of SCC-TAFs (n¼ 3). *Pp0.05 and ***Pp0.005 with respect to 0 mM
nintedanib were determined by Student’s t-test.
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growth and invasion of a panel of ADC and SCC cell lines that
were selected based on their EGFR and KRAS wild-type status to
mimic key genetic features of those patients that may be treated
with nintedanib (Bronte et al, 2016). As expected, the CM of
activated TAFs induced a robust (B1.5–2-fold) growth enhance-
ment with respect to serum-free control medium in both ADC and
SCC cell lines (Supplementary Figure S5). Remarkably, such
growth enhancement of carcinoma cells drop by B30–40% when
using CM from activated TAFs treated with 2 mM nintedanib in
ADC cell lines only (Figure 5B), whereas it remained virtually
unaltered in SCC cells (Figure 5C). The selective therapeutic effects
of nintedanib in ADC cells were even more dramatic when
analysing invasion data. Thus, CM of activated TAFs increased
markedly (B1.5–2.5-fold) the invasion through Matrigel-coated
Transwell inserts in both ADC and SCC cell lines with respect to
serum-free control medium (Supplementary Figure S5). In
contrast, the observed increase in invasion was reduced by B60–
70% when using CM from activated TAFs treated with 2 mM
nintedanib in ADC cell lines (Figure 5D), whereas no reduction
was observed in SCC (Figure 5E). These in vitro observations are in
qualitative agreement with the selective anticancer effects of
nintedanib observed in ADC patients in clinical trials (Reck et al,
2014; Novello et al, 2015). Moreover, these results reveal for the
first time that nintedanib in vitro induces a robust inhibition of
both the growth and invasive advantages provided by soluble
factors secreted by activated TAFs in ADC but not SCC.
Finally, to assess the potential contribution of carcinoma cells
themselves on the differential therapeutic effects of nintedanib
on the carcinoma–TAF cross-talk, we stimulated SCC cells with
CM from ADC-TAFs and vice versa. Four different scenarios
could be envisioned. Should the observed differential nintedanib
responses be attributed largely to TAFs only, then CM of ADC-
TAFs treated with nintedanib on SCC cells should induce
positive therapeutic responses as in Figure 5B and D, whereas the
opposite experiment (i.e., CM of SCC-TAFs on ADC cells)
should induce negative therapeutic responses as in Figure 5C and
E. Conversely, should the observed responses be attributed
largely to carcinoma cells, then the outcomes should be inverted
(i.e., CM of ADC-TAFs treated with nintedanib on SCC cells
should induce negative therapeutic responses, whereas CM of
SCC-TAFs on ADC cells should induce positive responses). The
results are shown in Figure 5F and G, where ADC and SCC
samples are labelled in blue and red, respectively, to facilitate the
experimental interpretation. CM of ADC-TAFs treated with
nintedanib on SCC cells elicited negative therapeutic responses
in terms of both growth and invasion (Figure 5F). In contrast,
the CM of SCC-TAFs treated with nintedanib on ADC cells
elicited a negative response in terms of growth but a positive
response in terms of invasion (Figure 5G). These results support
that there is a division of labour between TAFs and carcinoma
cells in which both SCC-TAFs and carcinoma cells themselves
(ADC and SCC) contribute to the observed differential
therapeutic responses to nintedanib.
High nintedanib doses induce vacuolar structures suggestive of
autophagy. During the course of our experiments we observed a
consistent formation of large vacuolar structures by phase contrast
microscopy in both normal fibroblasts and TAFs in all experimental
conditions (10% FBS, TGF-b1) at the highest nintedanib concentra-
tions examined (2–5mM) (Supplementary Figure S6). Similar vacuolar
structures have been recently reported in lung fibroblasts treated with
nintedanib elsewhere, and have been interpreted as indicators of
autophagy induction (Rangarajan et al, 2016). Autophagy is a highly
conserved biological process that allows the degradation and
recycling of cellular components. This degradative process has been
associated with cellular responses to different types of stress
(Schneider and Cuervo, 2014). Accordingly, it is conceivable that
high nintedanib concentrations may elicit an autophaghic stress
response in both control fibroblasts and TAFs.
DISCUSSION
Nintedanib is a multi-kinase inhibitor initially designed as a next
generation antiangiogenic drug (Hilberg et al, 2008) that has been
recently approved to treat patients with advanced lung ADC, based
on its selective therapeutic benefits on ADC patients (Reck et al,
2014; McCormack, 2015). However, the biological processes
underlying the selective therapeutic functions of this drug on
ADC (but not SCC) had remained undefined. We hypothesised
that such selective effects could be due, at least in part, to a larger
impact of nintedanib on ADC-TAFs compared to SCC-TAFs. To
test this hypothesis we used preclinical in vitro models to examine
the effects of nintedanib on primary TAFs derived from lung
cancer patients and on their tumour-promoting functions on
carcinoma cells. To minimise unwanted bias due to sample
variability, all TAFs were derived as tissue explants from surgical
patients selected upon very stringent criteria. In support to our
hypothesis, our results revealed that, in addition to its known
antiangiogenic effects (Hilberg et al, 2008; Cenik et al, 2013),
nintedanib may be therapeutically effective in ADC owing to its
ability to selectively target ADC-TAFs by reducing their activation,
which elicits anticancer effects through downregulation of secreted
soluble factors in TAFs that stimulate the growth and invasion of
carcinoma cells. In agreement with our observations, a significant
decrease in activated host fibroblasts was reported in tumour
mouse xenografts with ADC cells upon nintedanib treatment,
concomitantly with a reduction in tumour size and vessel density
(Cenik et al, 2013). The remarkable antifibrotic effects of
nintedanib are underscored by our novel observation that this
drug was able to markedly reduce the expression of activation
markers even in pre-activated fibroblasts. Conversely, our data
support that the lack of therapeutic benefit of nintedanib in SCC
patients is associated with the poor antifibrotic effect of this drug in
SCC-TAFs as well as to its failure to reduce the secretion of factors
in TAFs that stimulate the growth and invasion of SCC cells. In
addition to the direct contribution of TAFs, our mixed CM
experiments support that both ADC and SCC cells contribute
themselves to the positive therapeutic effects of nintedanib in ADC
but not in SCC, revealing a division of labour between TAFs and
carcinoma cells in modulating the subtype-specific nintedanib
responses.
Our study underscores the need to analyse the differential
secretome of ADC-TAFs and SCC-TAFs to ultimately identify
those secreted factors that may provide a pro-growth and
pro-invasive soluble microenvironment to ADC cells. Likewise
an analysis of the potential differential expression of the
corresponding receptors in ADC and SCC cells is warranted to
shed light on the mechanisms underlying the cross-talk between
TAFs and carcinoma cells in the selective therapeutic effects of
nintedanib in ADC. Although identifying these mechanisms was
beyond the scope of this study, we can envision potential
candidates based on previous studies. Specifically TAF stimula-
tion of carcinoma cell growth has been previously associated
with numerous secreted growth factors and cytokines such as
HGF, FGF, amphiregulin, CXCL12, TNF-a or Wnt. Likewise, a
variety of cytokines, proteases and pro-migratory extracellular
matrix components secreted by TAFs have been implicated in
the stimulation of carcinoma cell invasion including TGF-b,
CTGF, IL-6, MMPs, TIMPs, tenascin or SPARC (Bhowmick et al,
2004; Mueller and Fusenig, 2004; Bremnes et al, 2011; Ohlund
et al, 2014). However defining the precise driving factors awaits
future investigations.
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In addition to the secretion of pro-growth and pro-invasive
factors, TAFs may contribute indirectly to tumour progression by
hindering the diffusion of cancer therapeutics through increased
tortuosity and viscosity (Egeblad et al, 2010; Galgoczy et al, 2014),
owing to the abundant deposition of fibrillar collagens and other
fibrotic extracellular matrix components (Hinz et al, 2012; Jain
et al, 2014; Ohlund et al, 2014). Remarkably nintedanib down-
regulated the mRNA levels of the main fibrillar collagens in fibrosis
to a larger extent in ADC-TAFs compared to SCC-TAFs. Likewise
nintedanib elicited a larger downregulation of P4HA2 expression
in ADC-TAFs than in SCC-TAFs, which is an essential enzyme for
the intracellular stability of the procollagen triple helix that is
required for its effective secretion (Chen and Raghunath, 2009;
Schwarz, 2015). In agreement with our molecular observations, a
recent electron microscopy study reported a downregulation of
collagen fibril number and thickness in lung fibroblasts stimulated
with TGF-b1 in the presence of 1mM nintedanib (Knuppel et al,
2017). Based on these findings, it is conceivable that part of the
clinical benefits of the combination of nintedanib with docetaxel in
ADC patients are due to the downregulation of fibrillar collagens
elicited by nintedanib, for this downregulation may facilitate the
delivery of docetaxel to carcinoma cells by removing interstitial
barriers that hinder diffusion. In support of this interpretation, we
previously reported that the diffusivity of 4 kDa molecules (which
is close to the low molecular weight of docetaxel) through type I
collagen gels increased by B20% upon reducing collagen
concentration by B70% (Galgoczy et al, 2014), which is a similar
reduction to that elicited by 2 mM nintedanib on COL1A1 mRNA
expression in ADC-TAFs.
ADC-TAFs and SCC-TAFs exhibit distinct phenotypic altera-
tions in terms of growth and integrin signalling in basal conditions
(i.e., in the absence of either exogenous pro-growth or pro-
activation biochemical stimuli) (Puig et al, 2015). In the present
study we increased the list of subtype-specific aberrant features in
TAFs by reporting differential antifibrotic responses to nintedanib,
and revealed similar responses in ADC-TAFs and control
fibroblasts. Although the molecular underpinnings underlying all
these subtype-specific alterations in TAFs remains to be elucidated,
the differential antifibrotic responses to nintedanib strongly
suggest that TAF activation in ADC and SCC elicited by TGF-b1
may be regulated through distinct mechanisms. In support to this
interpretation we recently showed that the TGF-b pathway is
globally altered in lung TAFs as part of their epigenetic
reprogramming with respect to normal fibroblasts (Vizoso et al,
2015). In addition two recent studies have reported the nintedanib
inhibition of the activity of TGF-b receptor II as well as signalling
factors of the TGF-b pathway in lung fibroblasts stimulated with
TGF-b (Hostettler et al, 2014; Rangarajan et al, 2016). Thus, even
though the regulatory impact of nintedanib on the TGF-b pathway
remains incompletely defined (Rangarajan et al, 2016), it is
tempting to speculate that the differential antifibrotic effects of
nintedanib in ADC-TAFs and SCC-TAFs could be associated with
its ability to impact TGF-b signalling at different regulatory levels
in a subtype-specific fashion.
In addition to antifibrotic functions, nintedanib exhibited robust
antiproliferative effects in both normal lung fibroblasts and TAFs
when stimulated with 10% serum, which is rich in PDGF and other
fibroblast mitogens (Freshney, 1994). These findings are consistent
with previous observations that nintedanib efficiently blocks
PDGFR activation and proliferation in normal and fibrotic
fibroblasts in vitro and in vivo (Hostettler et al, 2014; Wollin
et al, 2014; Huang et al, 2016), and altogether reveal that this drug
elicits strong antiproliferative functions on lung fibroblasts in both
normal and diseased conditions. However, although such anti-
proliferative effects appear to be relevant in IPF and other fibrotic
disorders, we argue that the therapeutically relevant function of
nintedanib against the desmoplastic tumour stroma in ADC is its
antifibrotic rather than its antiproliferative effects, because TAFs
are largely quiescent and activated in vivo.
The highest nintedanib dose used in our study (5mM) induced
the formation of large vacuolar structures in both normal lung
fibroblasts and lung TAFs. Similar structures have been recently
reported in lung fibroblasts treated with increasing doses of
nintedanib up to 2mM elsewhere, and were directly associated with
autophagy (Rangarajan et al, 2016). In contrast, it is currently
unclear whether nintedanib induces vacuolar structures or
autophagy in lung cancer cells (Wollin et al, 2015; Shochet et al,
2016), although autophagy has been reported in different cancer
types in response to other tyrosine kinase inhibitors (Han et al, 2011;
Rikiishi, 2012). Because previous work has associated autophagy with
cell responses to different types of stress (Schneider and Cuervo,
2014), it is conceivable that fibroblast autophagy is a stress response
triggered by high nintedanib doses. However, even though the 2–
5mM range is larger than the maximum nintedanib concentration
reported in plasma (B1mM) during in vivo studies of this drug in
tumour xenografts (Hilberg et al, 2008), it remains unknown whether
stromal autophagy does occur in patients.
Our observed direct inhibitory effect of nintedanib on the
activation and tumour-promoting effects of ADC-TAFs expand
previous observations of a direct inhibitory effect of this drug on
stromal cell types involved in angiogenesis (Hilberg et al, 2008).
Collectively these observations underscore that nintedanib can be
considered an anti-stromal drug, for it inhibits multiple tumour-
promoting processes by targeting numerous cell types within the
tumour stroma. Accordingly, the synergistic therapeutic effects of
nintedanib combined with docetaxel reported in ADC patients
illustrate an emerging strategy in cancer therapeutics based on
combining drugs that target the aberrant tumour stroma with
either cytotoxic drugs or targeted drugs against carcinoma cells
(Mueller and Fusenig, 2004; Bremnes et al, 2011; Ohlund et al,
2014). However, it should be borne in mind that the latter
therapeutic strategy was unsuccessful in SCC patients, supporting
that the aberrant carcinoma–TAF cross-talk in SCC is mediated
through distinct mechanisms than in ADC. Yet, because our
preclinical models of carcinoma–TAF interactions captured the
selective therapeutic effects of nintedanib in ADC (but not SCC)
reported in clinical trials, we argue that these models may be useful
in identifying the mechanisms underlying the poor antifibrotic
response of SCC-TAFs to nintedanib.
In summary, our preclinical study reveals that the selective
therapeutic benefits of nintedanib combined with docetaxel in
ADC are associated with at least two complementary processes.
First, the direct antifibrotic effect of nintedanib on ADC-TAFs,
which reduces the deposition of fibrillar collagens, thereby
potentially reducing the physical barriers that may hinder the
delivery of docetaxel to cancer cells. Second, the reduction of the
secretion of yet unidentified soluble factors that stimulate the
growth and invasion of ADC cells. Likewise, our results support
that the latter therapeutic benefits of nintedanib are largely absent
in SCC due to the poor antifibrotic response of SCC-TAFs to this
drug. Collectively these results underscore the important role of
TAFs in modulating therapy responses.
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